Alexander's Inc

ALX is trading below key short-term EMAs after breaking the $259 support on heavy volume, confirming bearish medium-term momentum. Price is extended and deeply oversold, so selling now risks poor execution into a relief bounce. Selling should be deferred until a rebound into the 259–264 EMA resistance zone. The long-term trend remains bullish as long as the rising 200-day SMA holds.

• ↑Evorpacept and ALX2004 trials tracking for registrational studies by mid-2027.
• ↑Earnings yield ~22% indicates resource efficiency and possible undervaluation.
• ↓Weak balance sheet quality raises funding concerns for ongoing trials.